Cy­to­ki­net­ic­s' heart drug shows pos­i­tive re­sults af­ter FDA re­jec­tion of ear­li­er treat­ment: #ACC23

NEW OR­LEANS — Less than a week af­ter its heart fail­ure drug was re­ject­ed by the FDA, Cy­to­ki­net­ics is back with da­ta from an­oth­er pipeline can­di­date that the com­pa­ny is now tout­ing as core to its fu­ture.

At the Amer­i­can Col­lege of Car­di­ol­o­gy meet­ing in New Or­leans, Cy­to­ki­net­ics un­veiled new da­ta on its drug afi­camten in 41 pa­tients with non-ob­struc­tive hy­per­trophic car­diomy­opa­thy (HCM), a dis­ease where the heart mus­cle thick­ens and makes it hard to pump. While the pri­ma­ry end­points of the study cen­tered on safe­ty, pre­lim­i­nary ef­fi­ca­cy da­ta showed that the drug im­proved how just over half of pa­tients were clas­si­fied on a com­mon mea­sure used for heart fail­ure, known as their NY­HA class.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER